AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease
AbbVie presented Phase 2a TARGET-CD data showing its dual-targeting therapy ABBV-466 achieved endoscopic remission in 30.2% of Crohn's disease patients at Week 12, versus 21.3% on risankizumab and 18.0% on trosunilimab monotherapy. By Week 24 the gap widened, with 40.5% of ABBV-466 patients in endoscopic remission versus 22.4% and 20.0% on the monotherapy arms, in a heavily pretreated 300-patient population.
Key figures
- Drug Name
- ABBV-466 (risankizumab + trosunilimab)
- Phase Of Trial
- Phase 2a
- Sae rate abbv466
- 10.4%
- Patients enrolled
- 300
- Endoscopic remission abbv466 week12
- 30.2%
- Endoscopic remission abbv466 week24
- 40.5%
- Endoscopic remission risankizumab week12
- 21.3%
- Endoscopic remission risankizumab week24
- 22.4%
- Endoscopic remission trosunilimab week12
- 18.0%
- Endoscopic remission trosunilimab week24
- 20.0%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.